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Molecular evidence of synaptic pathology in the CA1 region
in schizophrenia
Natalie Matosin1,2,3, Francesca Fernandez-Enright2,4, Jeremy S Lum2, Martin Engel2, Jessica L Andrews2, Nils C Gassen1,
Klaus V Wagner1, Mathias V Schmidt1 and Kelly A Newell2
Alterations of postsynaptic density (PSD)95-complex proteins in schizophrenia ostensibly induce deﬁcits in synaptic plasticity, the
molecular process underlying cognitive functions. Although some PSD95-complex proteins have been previously examined in the
hippocampus in schizophrenia, the status of other equally important molecules is unclear. This is especially true in the cornu
ammonis (CA)1 hippocampal subﬁeld, a region that is critically involved in the pathophysiology of the illness. We thus performed a
quantitative immunoblot experiment to examine PSD95 and several of its associated proteins in the CA1 region, using post mortem
brain samples derived from schizophrenia subjects with age-, sex-, and post mortem interval-matched controls (n= 20/group). Our
results indicate a substantial reduction in PSD95 protein expression (−61.8%). Further analysis showed additional alterations to the
scaffold protein Homer1 (Homer1a: +42.9%, Homer1b/c: − 24.6%), with a twofold reduction in the ratio of Homer1b/c:Homer1a
isoforms (P= 0.011). Metabotropic glutamate receptor 1 (mGluR1) protein levels were signiﬁcantly reduced (−32.7%), and Preso,
a protein that supports interactions between Homer1 or PSD95 with mGluR1, was elevated (+83.3%). Signiﬁcant reduction in
synaptophysin (−27.8%) was also detected, which is a validated marker of synaptic density. These ﬁndings support the presence of
extensive molecular abnormalities to PSD95 and several of its associated proteins in the CA1 region in schizophrenia, offering
a small but signiﬁcant step toward understanding how proteins in the PSD are altered in the schizophrenia brain, and their
relevance to overall hippocampal and cognitive dysfunction in the illness.
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INTRODUCTION
The hippocampus is a region of the brain highly implicated in
schizophrenia pathology, with reports from several laboratories
consistently showing altered hippocampal form, volume, and
function in the illness.1 This region, and especially the cornu
ammonis (CA) sub regions, are crucial for cognitive functions
that are weakened in individuals with schizophrenia.2 Healthy
cognitive functions are largely dependent on dynamic changes
in synapse conﬁguration in the CA1 subﬁeld, an important
component of the hippocampus, which predominantly functions
to consolidate inputs from CA3.3 This process of synaptic plasticity
depends on the coordinated molecular activity of several proteins
packed tightly into the postsynaptic density (PSD), with disruption
to these molecules hypothesized to predispose neurons to synaptic
deﬁcits.4 Members of the PSD, particularly PSD95 and those with
which it forms a complex, are thus of increasing interest for
improving our understanding of the molecular processes underlying
memory impairments and hippocampal pathology in schizophrenia.
PSD95 is the most abundant protein at the PSD. It is a member
of the membrane-associated guanylate kinase family, a group of
proteins that have prominent roles in synaptic plasticity.5
Consistent with this role, PSD95 is critical for molecular organiza-
tion of the PSD6 and synapse stabilization.7 Previous studies have
analyzed PSD95 expression in multiple regions of brains from
patients with schizophrenia, although the results of these studies
could be considered inconclusive; within many regions, the data
are conﬂicting with either no change, increased, or decreased
PSD95 mRNA or protein reported across cortical (e.g., dorsolateral
prefrontal cortex) and subcortical (e.g., thalamus, nucleus accum-
bens, striatum) regions.8–18 Speciﬁcally within the hippocampus,
studies have either detected increased PSD95 protein levels in the
CA3 region of schizophrenia subjects,19 or no change in protein or
transcript expression in CA1, CA4, the parahippocampal gyrus and
dentate gyrus.8,9,19–21 Still, alterations of other important PSD95-
complex scaffold proteins in CA1 that could contribute to synaptic
pathology in schizophrenia cannot be excluded. For example,
decreased levels of the critical scaffold protein Homer1 were
reported in an unspeciﬁed region of the hippocampus,22 and
increased levels of its related multi-scaffolding protein, Tamalin,
was detected in CA1 in schizophrenia subjects.23 Preso proteins
have a similar role as Tamalin;24,25 these proteins have been
shown to be decreased in the dorsolateral prefrontal cortex in
schizophrenia,26 but their status in the hippocampus in schizo-
phrenia remains unknown.
In addition to its organizational role, PSD95 is one of the most stable
proteins at excitatory glutamate synapses.27,28 PSD95 is a major
regulator of protein–protein interactions, which is important for
processes such as intracellular trafﬁcking, cell-surface expression,
recycling, and activity of ionotropic and group I metabotropic
glutamate receptors (mGluRs), mGluR1 and mGluR5.29,30 These
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processes occur in concert with several other important scaffolding
proteins, including Homer1 and Tamalin.29–31 Previously detected
changes in Homer1 and Tamalin in the schizophrenia hippo-
campus22,23 might be related to alterations to glutamate transmission
(speciﬁcally via mGluR activity), protein–protein interactions, trafﬁcking,
and gene expression, contributing to glutamate dysregulation which is
apparent in the disorder. Indeed, recent studies have shown
disruptions to NR2B subunit-containing N-methyl-D-aspartate recep-
tors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid recep-
tors in the CA3 in schizophrenia,19 and accordingly, we recently found
evidence of increased mGluR5 protein levels in the CA1 region of
schizophrenia subjects relative to controls.23 It is unclear whether this
ﬁnding extends to mGluR1, which has not been examined in the
hippocampus in schizophrenia, although increased mGluR1a mRNA
and protein levels have been previously reported in the prefrontal
cortex of schizophrenia patients.32,33
Despite a recent report that disruptions to molecules in the PSD,
such as PSD95 and NR2B subunit-containing N-methyl-D-aspartate
receptors are speciﬁc to CA3 and not CA1 in schizophrenia,19 our
previously reported alterations of mGluR5 and Tamalin in CA123
suggest that disruptions to other important PSD95-complex
molecules may exist in the CA1 region in schizophrenia. In addition,
there is extensive evidence implicating CA1 in the illness; this
includes reduced CA1 volume in ﬁrst-episode schizophrenia
patients,34 deformity of CA1 being related to symptom severity
and antipsychotic response,35 and evidence that the CA1 subﬁeld is
hyperactive in the disorder.36 These studies point towards dysregula-
tion of the molecules that comprise this region. We therefore aimed
to explore the possibility that molecular abnormalities to important
PSD95-complex proteins occur in CA1 by conducting a quantitative
immunoblot study in a well-characterized post mortem brain cohort.
We examined PSD95, Homer1 (short [Homer1a] and long [Homer1b/
c] isoforms), Preso and mGluR1 proteins. Furthermore, levels of the
presynaptic protein synaptophysin were assessed, as this protein has
been shown to be a marker of synaptic density.37
RESULTS
PSD95
PSD95 is a major postsynaptic scaffold protein in the PSD, and
aberrations in this protein can lead to deleterious effects on
molecular synchronization in the PSD and synaptic plasticity.6,7
PSD95 was detected at the expected molecular weight of 95 kDa
using immunoblot. Our results showed that PSD95 protein levels
were signiﬁcantly reduced in schizophrenia subjects compared
with controls, after co-varying for brain pH and post mortem
interval (−61.84%; F1,34 = 24.985, Po0.001; Figure 1a); these were
variables associated with PSD95 protein levels (brain pH: r=
− 0.331, P= 0.042 in all subjects and r=− 0.542, P= 0.017 in
controls; post mortem interval: r= 0.544, P= 0.016 in schizophrenia
subjects; Supplementary Table 1). There were no effects of
hemisphere or illness duration on PSD95 protein measures, and
no correlation with lifetime antipsychotic drug medication
estimates. However a signiﬁcant effect of antidepressant medica-
tion was seen for PSD95 (yes n= 12; t17 = 3.289, P= 0.005, − 44.5%).
Homer1a and Homer1b/c
Homer1 is a major scaffold protein of the PSD, which is known to
have a role in the regulation of dendritic spine morphology and
synaptic function in hippocampal neurons.38 To assess protein
levels of Homer1 in the CA1 region in schizophrenia, the two main
splice variants of Homer1 were measured using antibodies speciﬁc
for Homer1a (short isoforms, an early immediate gene which acts
as a dominant negative for the Homer1 long isoforms) and
Homer1b/c (long isoforms, which are expressed constitutively).
These proteins were detected at the expected molecular weights
(Homer1a: 30 kDa, Homer1b/c: 40 kDa). A signiﬁcant increase in
protein levels of Homer1a was detected in schizophrenia subjects
relative to controls, after co-varying for freezer storage time
(+42.92%; F1,34 = 9.751, P= 0.004; Figure 2a), which was a variable
that correlated with Homer1a protein expression in control
subjects only (r= 0.545, P= 0.013; Supplementary Table 1).
Conversely, Homer1b/c levels were signiﬁcantly reduced, after
co-varying for freezer storage time (−24.55%, F1,34 = 4.810,
P= 0.035; Figure 2b), which correlated with Homer1b/c levels in
all subjects (r=− 0.341, P= 0.039, Supplementary Table 1). These
aberrations in Homer1a and Homer1b/c protein levels resulted in
a signiﬁcant twofold decrease in the ratio of Homer1b/c to
Homer1a from 29.11 ± 18.19 to 15.12 ± 13.50 (t35 =− 2.679,
P= 0.011), suggesting an imbalance of these proteins in schizo-
phrenia. There were no effects of hemisphere on Homer1
Figure 1. Scatterplots depicting normalized protein levels of (a) PSD95 and (b) synaptophysin in the CA1 region of healthy control (HC) and
schizophrenia (SZ) subjects. Raw means (before co-varying the data) are depicted. ***Po0.001.
Hippocampal pathology in CA1 in schizophrenia
N Matosin et al
2
npj Schizophrenia (2016) 16022 Published in partnership with the Schizophrenia International Research Society
measures, and no correlation with lifetime antipsychotic drug
medication estimates, or illness duration. However, a signiﬁcant
effect of antidepressant medication was seen on Homer1b/c levels
(yes n= 11; t15 = 2.950, P= 0.010, − 22.5%).
Preso
Preso proteins facilitate PSD95/Homer1 long-isoform interactions
with group I mGluRs, and reportedly have a role in dendritic spine
morphogenesis.24,25 Considering the aforementioned alterations
of PSD95 and Homer1, we additionally assessed protein levels of
Preso in the CA1 region in schizophrenia. Preso was detected at
the expected molecular weight of 144 kDa. Preso protein
expression was signiﬁcantly higher in schizophrenia subjects
compared with controls (+83.30%; t37 = 14.142, Po0.001;
Figure 2c). There were no effects of sample characteristics (age
at death, pH, post mortem interval, RNA integrity number (RIN),
brain weight, and freezer storage time) on Preso protein levels, or
effects of hemisphere, antidepressant, or lifetime antipsychotic
drug medication estimates. However, Preso protein levels were
associated with age of disease onset in schizophrenia subjects
(r= 0.498, P= 0.030).
mGluR1
mGluR1 is a key modulator of glutamatergic neurotransmission
and synaptic plasticity, and its activity and trafﬁcking is regulated
by Homer1 and PSD95 via protein–protein interactions in the
PSD.30 mGluR1 was detected at two molecular weights, thus
monomer (150 kDa), dimer (250 kDa), and total (sum of monomer
and dimer) levels are reported to assess protein levels of mGluR1.
Total mGluR1 protein levels were signiﬁcantly lower in schizo-
phrenia subjects relative to controls maintained after co-varying
for post mortem interval (−32.65%; F1,30 = 14.586, P= 0.001;
Figure 3a). Similarly, levels of mGluR1 monomer were reduced
by − 67.22% (F1,33 = 49.489, Po0.001, Figure 3b) and mGluR1
dimer by − 66.41% (dimer: F1,33 = 60.885, Po0.001; Figure 3c),
after also co-varying for post mortem interval, which was signiﬁ-
cantly correlated with all mGluR1 measures (Supplementary
Table 1). There were no effects of hemisphere, illness duration,
antidepressant, or lifetime antipsychotic drug medication esti-
mates on mGluR1 proteins.
Synaptophysin
Prior studies have shown that levels of synaptophysin are
a reliable marker of synaptic density.37 Synaptophysin was thus
also assessed using immunoblot, to determine whether the
molecular alterations observed in the CA1 region in schizo-
phrenia might extend to deﬁcits in synapse numbers. Synapto-
physin was detected at the expected molecular weight of 33 kDa.
Protein levels of synaptophysin were signiﬁcantly reduced in
schizophrenia subjects compared with controls (−27.84%;
t36 =− 3.558, P= 0.001; Figure 1b). There were no effects of
sample characteristics (age at death, pH, post mortem interval,
RIN, brain weight, and freezer storage time) on synaptophysin
protein levels, or effects of hemisphere, age of disease onset,
antidepressant, or lifetime antipsychotic drug medication
estimates.
Protein–protein associations in schizophrenia relative to controls
To assess the hypothesis of abnormal protein–protein interactions
at the synapse in schizophrenia, we ran exploratory analyses to
assess the correlations between Group I mGluRs with these
scaffold proteins (note that protein levels of mGluR5 and Tamalin
were drawn from our previous work13). In controls, mGluR1 total
levels were signiﬁcantly correlated with PSD95 (r= 0.612, P= 0.012)
and Homer1a (r=− 0.654, P= 0.004), whereas mGluR1 monomer
levels were correlated with Homer1a (r=− 0.612, P= 0.005) and
Homer1b/c (r= 0.549, P= 0.015). mGluR1 dimer correlated with
PSD95 (r= 0.530, P= 0.020); all these associations were not
detected in the schizophrenia group. mGluR1 monomer levels
were signiﬁcantly associated with Tamalin in control subjects
(r= 0.500, P= 0.029) but not schizophrenia subjects, whereas
mGluR1 total levels were associated with Tamalin in schizophrenia
subjects (r= 0.526, P= 0.036), but did not reach signiﬁcance in
controls (r= 0.463, P= 0.061). No associations of mGluR5 and the
scaffold proteins were observed in controls, although mGluR5
monomer and dimer levels were highly correlated with PSD95
(r40.621, Po0.005) and Tamalin (r40.611, Po0.005)23 in the
schizophrenia group. A summary of these results are presented in
Table 1, and the complete set of correlations for all other proteins
measured in these subjects and regions are included in
Supplementary Table 2.
Figure 2. Scatterplots depicting normalized protein levels of (a) Homer1a, (b) Homer1b/c, and (c) Preso, in the CA1 region of healthy control
(HC) and schizophrenia (SZ) subjects. Raw means (before co-varying the data) are depicted; Homer1a and Preso are depicted in the natural
logarithm form owing to abnormal distribution of the data. **Po0.01, ***Po0.001.
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DISCUSSION
This study shows extensive disruption to PSD95 and several
important PSD95-complex proteins in post mortem samples from
the CA1 hippocampal region of schizophrenia subjects relative
to matched controls. In particular, substantial decreases in PSD95
and synaptophysin were observed, as well as increases and
decreases in other related postsynaptic proteins suggesting
altered protein–protein interactions in the illness. These data
support the currently proposed model of hippocampal dysfunc-
tion in schizophrenia,1 centered on reduced volume and
hyperactivity of the hippocampus which has been consistently
reported in the illness.36,39–43
Prior mechanistic studies show that PSD95 is required to sustain
molecular organization of the PSD6 and synapse stabilization.7
Deﬁciencies in PSD95 induced by RNA interference knockdown
inﬂicts widespread deletions of entire segments of the PSD in rat
hippocampal neurons,6 and impedes normal development of
synapse structure and function after synaptic potentiation.7 The
substantial reduction in PSD95 observed in this study (−62%) may
therefore suggest the existence of deleterious effects to the PSD in
the CA1 region in the illness. Similarly, synaptophysin proteins
were reduced by almost 30% in the CA1 region of schizophrenia
subjects compared to controls. Considering 95% of PSD95 protein
is localized to synapses44 and the levels of synaptophysin and
PSD95 strongly correspond to synapse numbers,45,46 these data
are strongly suggestive of reduced synapse number in the CA1
region of schizophrenia subjects. To our knowledge, there are no
studies examining possible changes to synapse density in the CA1
region of the schizophrenia brain, although reductions in gene
expression of transcripts associated with dendritic spines has been
reported in this region.47 In addition, increased spine density of
pyramidal cell apical dendrites was reported in the adjacent CA3
region,19 which might be compensatory for synaptic alterations in
CA1. An extension of this work in CA1 will be important to conﬁrm
the molecular ﬁndings of the current study and to determine on
which synapses in CA1 these deﬁcits are occurring (e.g., Schaffer
collaterals), as well as how this ﬁts with the ﬁndings in CA3.
The extensive aberrations in other PSD95-complex proteins in
this study support the presence of altered synapses and plasticity
in CA1 in schizophrenia. It is now established that Homer1
cooperates with PSD95 to form the architectural basis required
for PSD receptor clustering and the appropriate signaling in
response to prolonged neuronal stimuli.48 Upregulation of
Homer1a proteins and downregulation of Homer1b/c were
observed in this study, resulting in a twofold decrease in the
ratio of Homer1b/c to Homer1a. The relative balance of Homer1b/
c:Homer1a isoforms is considered to be functionally signiﬁcant in
the regulation of plasticity, dendritic spine morphology, and
hippocampal-dependent cognitive function,49 with our data thus
supporting the presence of synaptic dysregulation in CA1 in
schizophrenia. Disruption of Homer1 function may also lead to
reduced trafﬁcking of group I mGluRs, their coupling to IP3
receptors and calcium homeostasis, which are processes required
to appropriately direct plasticity.50 The Homer1b/c:1a ratio is
described to act as a molecular switch that redirects signaling
through either mGluR1 or mGluR5.51,52 mGluR1 protein levels
were reduced in this study, suggesting that it has an inverse
relationship with mGluR5, which are increased in the same
region and subjects.23 In addition, Preso and Tamalin, which are
proteins that facilitate PSD95/Homer1 long isoforms with
mGluR1/5,24,25,29,31 were also upregulated, potentially in response
Figure 3. Scatterplots depicting normalized (a) total, (b) monomer, and (c) dimer measures of mGluR1 protein levels in the CA1 region of
healthy control (HC) and schizophrenia (SZ) subjects. Raw means (before co-varying the data) are depicted; mGluR1 monomer and dimer
levels are depicted in the natural logarithm form owing to abnormal distribution of the data. mGluR1 monomer levels were furher
transformed (Ln[x]+1) to account for negative values. ***Po0.001.
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to PSD95/Homer1 downregulation and an imbalance of mGluR1:
mGluR5 levels. Preso proteins additionally direct synaptic plasticity
by facilitation of the PSD95-complex to ﬁlamentous (F)-actin;25
overexpression of Preso might thus represent an attempt to
reconnect PSD95 and F-actin molecules to repair deﬁcits in
plasticity.
A consistent ﬁnding in the hippocampus of schizophrenia
patients—and CA1 in particular—is increased blood volume,
supporting evidence of CA1 hyperactivity in the illness.36,39–43
Increased activity of CA1 is hypothesized to arise from deﬁcient
GABAergic ﬁring in CA3, causing disinhibition of pyramidal cell
inputs and increasing glutamate release onto CA1.53 Although it
might be hypothesized that glutamate excitotoxicity leads to
neuronal and thus volume loss in this region, the total number of
neurons in the hippocampus is unaltered in schizophrenia.54–57
A recent immunostaining study however indicates reduced
glutamic acid decarboxylase-immunoreactive neuropil density in
post mortem schizophrenia hippocampal sections including CA1,58
which could contribute to hippocampal volume loss. In support,
small deﬁcits of interneuron populations such as parvalbumin-
and somatostatin-positive interneurons have been reported in the
hippocampus of schizophrenia subjects,55,59–61 ostensibly indu-
cing hyperactivity via the disinhibition of pyramidal cells.62 It is
interesting to note that the reduced levels of mGluR1 proteins in
this study were detected with an antibody speciﬁc for the
mGluR1α isoform, which is exclusively localized to interneurons of
the CA1 region.63,64 Conversely, mGluR5, which is expressed on
CA1 pyramidal neurons,63 was increased in the same region and
subjects.23 The close correlation of mGluR1α and PSD95 seen in
controls, but not schizophrenia subjects (Table 1), additionally
suggests that the pathological reduction in PSD95 occurs along-
side mGluR1α, which is consistent with the loss of interneurons
observed in CA1.55,59–61
It should also be considered that our ﬁndings are in contrast to
a recent report of unaltered PSD95 protein levels in the CA1
region in a similar sized schizophrenia post mortem cohort.19
Differences in age at death and manner of death may account
for these inconsistent ﬁndings. However, considering the exis-
tence of a rostro-caudal gradient of gene expression in the
hippocampus,65,66 it is plausible that small differences in dissec-
tion procedures and region collected in this study relative to the
prior study19 have led to cohort-dependent differences and
diverging results. Slight anatomical differences between samples
may also explain the high levels of variability observed in control
subjects in this study for PSD95 and Homer1b/c protein measures;
this ﬁnding is opposite to typical observations in previous post
mortem studies (i.e., greater spread of results in patients compared
with controls). However, PSD95 and Homer1 proteins are also
highly susceptible to activity- and experience-dependent
change,67,68 especially in the CA1 region which is necessary for
proper plastic processes. The spread of PSD95 and Homer1b/c:1a
ratio may reﬂect a normal state, where these proteins are respond-
ing well to activity, experience and other stimuli. Alternatively, the
lack of spread in schizophrenia subjects may represent an inability
of patients to process or react to various stimuli, leading to altered
experience- and activity-dependent molecular responses and
ultimately disrupted plasticity.
A possible limitation of this study is the confounding effect of
medication, as all schizophrenia subjects were medicated with
antipsychotic drugs in this study. We did not observe any
correlations with our protein measures and antipsychotic drug
exposure. Our previous work additionally reports no inﬂuence of
typical or atypical antipsychotic drug treatment on mGluR5, Preso
and Tamalin protein expression in the hippocampus of rats.23,69
Others have shown that antipsychotic medication might inﬂuence
transcript and protein expression of PSD95 and Homer1, but these
were in regions other than the hippocampus.70 It may be of
relevance that we also observed a non-signiﬁcant borderlineT
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correlation between synaptophysin with lifetime antipsychotic
drug exposure, considering the typical antipsychotic Triﬂuoper-
azine has been shown to reduce synaptophysin transcript
expression within the Schaffer collateral region of CA1.71
Furthermore, chlorpromazine equivalents were used as an
indicator of antipsychotic drug exposure in this study, which is
an approach limited by the high rate of medication non-
compliance among patients.72 Chlorpromazine equivalents are
based on dopamine receptor D2 occupancy, which is relevant for
typical antipsychotic medication history, but has limited value for
patients who have a history of atypical antipsychotic drug
exposure. It is also notable that an association of antidepressant
drug exposure (yes/no) was observed with protein levels of
Homer1b/c and PSD95. No data exists regarding the effects of
antidepressant drug exposure on Homer1 or PSD95 proteins in
the hippocampus, although Feyissa et al.73 reported no anti-
depressant effects in the anterior prefrontal cortex.
In summary, this study provides evidence of alterations to
important PSD95-complex proteins in the CA1 region in subjects
with schizophrenia. These included PSD95, Homer1 long and short
isoforms, Preso, mGluR1, synaptophysin, as well as Tamalin23 and
mGluR523 proteins, which we have reported previously. Although
the mechanisms and morphological effects of these alterations
were not explored here, we speculate that there are changes
to synaptic plasticity and/or neurophil loss in the CA1 region
in schizophrenia, contributing to the increased activity and
decreased volume of the hippocampus consistently observed in
the disorder. Although the circumstantial support is persuasive
these signiﬁcant molecular leads require follow-up with morpho-
logical studies to conﬁrm the existence of aberrant plasticity in the
CA1 region in patients with schizophrenia.
MATERIALS AND METHODS
Post mortem brain samples
Human post mortem brain samples were from the NSW Brain Tissue
Resource Centre (Sydney, NSW, Australia). Samples were derived from the
CA1 region of 20 schizophrenia subjects (diagnosed according to the DSM-
IV) and 20 controls (no history of psychiatric disorder), with these subjects
matched according to post mortem interval, tissue pH, age at death, and
RIN (Table 2); the sample was adequately powered (0.8–0.9) to detect
expression differences (24%) owing to disease. Specimens were processed
and characterized according to Weickert et al.,74 with samples in this study
taken from the same subjects. Regarding dissection procedure, brain tissue
was collected and dissected fresh at the level of the geniculate nucleus,
and then frozen. From this level of dissection, architecture of the
hippocampus could be visually veriﬁed and CA1 was manually dissected.
When difﬁculty was encountered in identifying the hippocampal sub
regions, tissue was further cryosectioned to conﬁrm anatomical location.
All subjects with schizophrenia were prescribed antipsychotics at the time
of death and a lifetime chlorpromazine equivalent was calculated for each
patient. This study was approved by the Human Research Ethics
Committee at the University of Wollongong (HE99/222).
Quantitative immunoblotting
Relative protein densities were determined by immunoblot analysis as
described previously, with minor modiﬁcations to increase signal.26 Brieﬂy,
5 μg of total protein was loaded per subject (blind to diagnosis) and run in
duplicate. Probing was performed using the following primary antibodies:
PSD95 (1:500, Millipore, Sydney, NSW, Australia, MAB1598); Homer1a
(1:100, Santa Cruz, CA, USA, sc-8922), Homer1b/c (1:2000, ab97593, Abcam,
Melbourne, VIC, Australia); Preso (1:1000, Santa Cruz, sc-242862); mGluR1
(1:250, Millipore, 07–617); synaptophysin (1:1000, Life Technology,
Scoresby, VIC, Australia, 8H2L12 (monoclonal)). Blots were subsequently
incubated with horseradish peroxidase-conjugated secondary antibody (anti-
rabbit: 1:1000, Millipore, ap307P) and visualized using enhanced chemilumi-
nescent detection kit (BioRad, Gladesville, NSW, Australia). Band densities
were quantiﬁed with the Gel Doc 2200 Pro (Carestream Molecular Imaging,
Woodbridge, CT, USA) and Carestream Molecular Imaging software (v5.0.4.44,
Carestream Molecular Imaging). All proteins were within the linear range of
detection for 5 μg protein (see Supplementary Information for details).
Densitometry values for each sample were normalized to β-actin (1:5000;
MAB1501, Millipore) by dividing protein values by β-actin values to account
for differences in protein loadings between subjects; notably, β-actin was
unaltered across cohorts.23,75 Values were subsequently normalized to a
pooled sample (consisting of 10 pooled post mortem brain samples, with the
same pool used across all experimental runs) to also account for potential
gel-to-gel variability.
Statistical analyses
Statistical analyses were performed with SPSS (Chicago, IL, USA, version 19).
Signiﬁcance was set to Po0.05 and data are presented as mean± s.e.m.
The average of the duplicates for each protein measure was used for
statistical analyses. PSD95, Homer1b/c, mGluR1 (total) and synaptophysin
protein levels were normally distributed. mGluR1 (monomer) and mGluR1
(dimer) were skewed to the left, while Homer1a and Preso were skewed to
the right (Kolmogorov–Smirnov: d= 0.089–0.237; Po0.033); normalized
distribution for these proteins was achieved by transforming to the natural
logarithm of the relative protein values. Outliers were screened as
mean± 2 s.d. and removed. Two subjects were removed on average from
each protein analysis.
Spearman’s correlations were implemented to analyze whether sample
characteristics (age at death, pH, post mortem interval, RIN, brain weight,
and freezer storage time) were associated with protein measures in all
subjects and control and schizophrenia subjects individually. Where
signiﬁcant correlations were detected, analyses of covariance were
performed to compare schizophrenia and control subjects, with signiﬁcant
correlates taken as covariates; where no signiﬁcant correlations were
detected, analysis was performed using independent t-tests. Two-way
ANOVAs were used to determine main and interactive effects of diagnosis
and brain hemisphere (left/right); gender analyses were not included
owing to power constraints. In the schizophrenia group, lifetime
antipsychotic drug history, age of disease onset, and duration of illness
were also analyzed using Spearman’s correlations to extricate any potential
effects on the data. Associations with antidepressant exposure (yes/no)
with each of the protein levels were assessed using independent t-tests.
Finally, the potential for differences in protein–protein associations
between schizophrenia and controls groups were also assessed using
Spearman’s correlations.
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